FDA Distinguishes 7-OH Products From Natural Kratom Leaf

One of the most important recent developments for the responsible U.S. kratom industry is the growing regulatory distinction between natural kratom leaf and concentrated 7-hydroxymitragynine products.

In July 2025, the FDA announced efforts to restrict products containing concentrated 7-OH, a compound related to the kratom plant.

Crucially, the agency stated that this particular action was focused on concentrated 7-OH products and was not directed at natural kratom leaf.

What is 7-hydroxymitragynine?

7-hydroxymitragynine, often shortened to 7-OH, is an alkaloid associated with kratom.

It can occur naturally in kratom leaf in trace quantities. However, some commercial products contain concentrated, enhanced or manufactured levels that are far greater than those typically present in natural leaf material.

These products may be sold as:

Tablets
Gummies
Liquid shots
Extracts
Flavored concentrates
Products labeled only as "kratom"

The FDA has warned that concentrated 7-OH products can carry a greater risk of sedation, dependence and other opioid-related effects than traditional kratom leaf products.

Why the distinction matters

For years, the word "kratom" has been used to describe a wide range of products.

That category can include minimally processed leaf powder, brewed tea, capsules, concentrated extracts and manufactured 7-OH products.

Treating all of these as identical can create confusion for consumers, healthcare professionals and regulators.

The FDA's targeted action recognizes that a high-potency 7-OH tablet may have a substantially different composition and risk profile from natural kratom leaf.

The distinction does not mean that natural kratom is FDA-approved or risk-free. The FDA continues to advise consumers against using kratom and notes that no kratom products are approved as drugs or over-the-counter treatments.

However, product-specific regulation is generally more informative than placing every kratom-related item into one undifferentiated category.

Positive news for responsible natural-leaf businesses

Retailers and manufacturers that focus on appropriately tested natural kratom leaf may benefit from clearer product definitions.

A responsible natural-leaf business should be able to demonstrate:

The product is made from Mitragyna speciosa leaf
The product does not contain artificially elevated 7-OH
The ingredient list is complete
The alkaloid content has been tested
The product is free from undisclosed substances
The serving information is clearly displayed
The label does not make illegal medical claims
The product is not marketed to minors

Clear distinctions can help protect reputable suppliers from being grouped together with manufacturers selling high-potency synthetic or semisynthetic products under the kratom name.

Industry standards can improve kratom product quality

The American Kratom Association operates a voluntary Good Manufacturing Practices Standards Program for participating kratom companies.

The program evaluates manufacturing, packaging, labeling and product-storage practices. Participating companies are expected to undergo independent third-party audits.

Because this is an industry-run program, participation is not equivalent to FDA approval or government certification.

Still, independent auditing, contaminant testing and accurate labeling can provide additional information to consumers trying to evaluate kratom vendors.

Useful testing may include:

Mitragynine concentration
7-OH concentration
Salmonella and other microbial contaminants
Heavy metals
Pesticide residues
Product identity
Undeclared pharmaceutical ingredients
Batch-to-batch consistency

Why transparent labeling benefits consumers

Consumers should not have to guess whether a product is natural leaf, an extract or a concentrated 7-OH preparation.

Product labels should clearly disclose:

The type of kratom material
The amount per serving
The number of servings per package
The mitragynine concentration
The 7-OH concentration
All additional botanicals
Any sweeteners or active additives
The manufacturer and batch number
Appropriate consumer warnings

Transparent labeling allows customers to make more informed decisions and helps businesses identify noncompliant products before placing them on store shelves.

Responsible retailers should avoid broad wellness claims

Kratom businesses should not claim that natural leaf products cure pain, treat anxiety, eliminate opioid withdrawal or provide a safe substitute for prescription treatment.

These claims can mislead consumers and potentially cause someone to delay appropriate medical care.

A responsible retailer can instead focus on factual information:

Kratom comes from a Southeast Asian tree.
Different products can contain very different alkaloid concentrations.
Natural leaf and concentrated 7-OH products are not equivalent.
Kratom can cause dependence and withdrawal.
Kratom may interact with medications or other substances.
Consumers should understand exactly what they are purchasing.

A more informed future for the kratom industry

The FDA's distinction between concentrated 7-OH and natural kratom leaf does not resolve every regulatory or scientific concern.

It does create an opportunity for more precise conversations.

For consumers searching for 7-OH versus kratom, natural kratom leaf, safe kratom products, kratom extract differences or FDA kratom news, the most important takeaway is that product composition matters.

Natural leaf powder, standard extracts and concentrated 7-OH products should be accurately identified, independently tested and evaluated according to their actual contents.

A sustainable kratom industry will depend on businesses that prioritize transparency over potency, responsible labeling over exaggerated claims and consumer protection over short-term sales.